UCB PHARMA SA
π§πͺBelgium
- Country
- π§πͺBelgium
- Ownership
- Public, Subsidiary
- Established
- 1928-01-01
- Employees
- 9K
- Market Cap
- $34.9B
Open Label Trial to Study the Long-term Safety and Efficacy of Seletracetam for the Treatment of Epilepsy
Phase 3
Withdrawn
- Conditions
- Epilepsy
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2012-05-28
- Lead Sponsor
- UCB Pharma
- Registration Number
- NCT00175851
A Dose-ranging Study With Brivaracetam in Patients From 16 to 65 Years With Refractory Partial Onset Seizures.
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2018-10-02
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 210
- Registration Number
- NCT00175825
A Study of the Safety and Effectiveness of Lyophilized Certolizumab Pegol in the Treatment of Signs and Symptoms of Rheumatoid Arthritis and in Prevention of Joint Damage in Patients With Active Rheumatoid Arthritis
Phase 3
Completed
- Conditions
- Rheumatoid Arthritis
- Interventions
- Biological: Certolizumab Pegol
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2020-03-26
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 857
- Registration Number
- NCT00175877
- Locations
- πΊπΈ
140, Orlando, Florida, United States
π¨π±49, Santiago de Chile, Chile
πΊπΈ136, Tampa, Florida, United States
Follow-up Trial to Evaluate Long-term Safety and Efficacy of Brivaracetam in Subjects Suffering From Epilepsy
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2021-08-17
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 853
- Registration Number
- NCT00175916
- Locations
- π§πͺ
506, Brugge, Belgium
π§πͺ505, Leuven, Belgium
π¦πΉ509, Graz, Austria
A Study of Brivaracetam in Subjects With Partial Onset Seizures
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2015-04-13
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 157
- Registration Number
- NCT00175929
A Study of Liquid Certolizumab Pegol as Additional Medication to Methotrexate in the Treatment of Signs and Symptoms of Rheumatoid Arthritis and in Prevention of Joint Damage in Patients With Active Rheumatoid Arthritis
Phase 3
Completed
- Conditions
- Rheumatoid Arthritis
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2020-12-01
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 590
- Registration Number
- NCT00160602
A Study of the Safety and Effectiveness of Liquid Certolizumab Pegol in the Treatment of Signs and Symptoms of Rheumatoid Arthritis and in Prevention of Joint Damage in Patients With Active Rheumatoid Arthritis
Phase 3
Completed
- Conditions
- Rheumatoid Arthritis
- Interventions
- Biological: Certolizumab Pegol
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2020-03-27
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 567
- Registration Number
- NCT00160641
- Locations
- πΊπΈ
172, Palm Desert, California, United States
πΊπΈ170, Santa Maria, California, United States
πΊπΈ194, Whittier, California, United States
Levetiracetam Treatment in Adult Subjects With Parkinson's Disease Experiencing Troublesome Dyskinesias
Phase 2
Completed
- Conditions
- Idiopathic Parkinson Disease
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2013-12-06
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 30
- Registration Number
- NCT00160576
Study to Evaluate the Safety and Efficacy of Levetiracetam in Patients Suffering From Idiopathic Generalized Epilepsy With Primary Generalized Tonic-clonic Seizures
Phase 3
Completed
- Conditions
- Generalized Convulsive Epilepsy
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2013-11-26
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 154
- Registration Number
- NCT00160550
Open Label Safety and Efficacy Study of Levetiracetam in Korean Patients With Epilepsy
Phase 3
Completed
- Conditions
- Epilepsy, Partial
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2013-11-26
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 100
- Registration Number
- NCT00160628
Β© Copyright 2025. All Rights Reserved by MedPath